Lillian Smith - 01 Apr 2023 Form 3 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role: VP, Corporate Counsel
Signature: /s/Lillian Smith
Issuer symbol: ALLO
Transactions as of: 01 Apr 2023
Net transactions value: $0
Form type: 3
Filing time: 05 Apr 2023, 18:38:24 UTC
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ALLO	Common Stock						83,845	01 Apr 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ALLO	Stock Option (Right to Buy)							01 Apr 2023	Common Stock	37,724	$13.31	Direct	F2
holding	ALLO	Stock Option (Right to Buy)							01 Apr 2023	Common Stock	24,428	$5.04	Direct	F3
holding	ALLO	Stock Option (Right to Buy)							01 Apr 2023	Common Stock	78,750	$4.77	Direct	F4
holding	ALLO	Stock Option (Right to Buy)							01 Apr 2023	Common Stock	4,927	$9.69	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 64,366 shares of restricted stock units.
F2	1/3rd of the shares subject to the option vest on each anniversary measured from July 19th, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date
F3	25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.
F4	25% of the shares subject to the stock option shall vest on August 27, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter.
F5	25% of the shares subject to the stock option shall vest on March 13, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter.